{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:16:49Z","timestamp":1790482609398,"version":"4.1.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"\n Background.<\/jats:title>\n Cytomegalovirus (CMV) donor-positive\/recipient-negative (D+R\u2013) serostatus is independently associated with worse allograft and patient survival across solid organ transplant (SOT) types. We characterized trends in CMV D+R\u2013 serostatus among adult SOT recipients performed in the United States.<\/jats:p>\n <\/jats:sec>\n \n Methods.<\/jats:title>\n Donor (D) and recipient (R) CMV serostatus and demographic factors were obtained from the Scientific Registry of Transplant Recipients for persons \u226518 y undergoing a first SOT between January 1, 2000, and December 31, 2020. The proportions of D+R\u2013 SOTs over time were assessed using Chi square for trend and modeled through 2040. Factors associated with D\/R seropositivity were assessed using logistic models.<\/jats:p>\n <\/jats:sec>\n \n Results.<\/jats:title>\n \n Among 472\u2009549 SOTs, the average proportion of D+R\u2013 SOTs increased significantly among kidney, liver, heart, and lung between 2000 to 2009 and 2010 to 2020: 18.0% to 18.3% (\n P<\/jats:italic>\n \u2009=\u20090.034), 19.4% to 21.8% (\n P<\/jats:italic>\n \u2009<\u20090.001), 22.2% to 25.5% (\n P<\/jats:italic>\n \u2009<\u20090.001), and 23.6% to 27.0% (\n P<\/jats:italic>\n \u2009<\u20090.001), respectively. The increased proportion over time resulted from a disproportionate increase in R\u2013 (34.9% to 37.0% for all organ types,\n P<\/jats:italic>\n \u2009<\u20090.001) and a smaller corresponding change in D+ (60.8% to 60.3%,\n P<\/jats:italic>\n \u2009<\u20090.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions.<\/jats:title>\n The proportion of high-risk CMV D+R\u2013 SOTs increased significantly across all organs and is projected to continue to increase. These findings inform population-level strategies to mitigate the negative impact of CMV D+R\u2013 in SOT.<\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/tp.0000000000004352","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T12:00:10Z","timestamp":1664452810000},"page":"988-993","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":20,"title":["Increasing Proportion of High-risk Cytomegalovirus Donor-positive\/Recipient-negative Serostatus in Solid Organ Transplant Recipients"],"prefix":"10.1097","volume":"107","author":[{"given":"Hannah","family":"Imlay","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Utah, Salt Lake City, UT."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn M.","family":"Wagener","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Vutien","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Washington, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Perkins","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Washington, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Singh","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit P.","family":"Limaye","sequence":"additional","affiliation":[{"name":"Division of Allergy and Infectious Diseases, Department of Internal Medicine, University of Washington, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/lt.26045","article-title":"Association of donor and recipient cytomegalovirus serostatus on graft and patient survival in liver transplant recipients.","volume":"27","author":"Vutien","year":"2021","journal-title":"Liver Transpl"},{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/ajt.15183","article-title":"Cytomegalovirus mismatch still negatively affects patient and graft survival in the era of routine prophylactic and preemptive therapy: a paired kidney analysis.","volume":"19","author":"Leeaphorn","year":"2019","journal-title":"Am J Transplant"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/TP.0000000000003961","article-title":"Cytomegalovirus donor seropositivity negatively affects survival after heart transplantation.","volume":"106","author":"Heim","year":"2022","journal-title":"Transplantation"},{"key":"R4-20250604","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.healun.2019.08.001","article-title":"The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult lung and heart-lung transplantation report\u20142019; focus theme: donor and recipient size match.","volume":"38","author":"Chambers","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1086\/508173","article-title":"Seroprevalence of cytomegalovirus infection in the United States, 1988\u20131994.","volume":"43","author":"Staras","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1086\/652438","article-title":"Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988\u20132004.","volume":"50","author":"Bate","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"e704","DOI":"10.1097\/TXD.0000000000001147","article-title":"Geographic distribution of cytomegalovirus serology in kidney and pancreas transplant recipients in the United States.","volume":"7","author":"Jorgenson","year":"2021","journal-title":"Transplant Direct"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/TP.0000000000003887","article-title":"The clinical and economic benefit of CMV matching in kidney transplant: a decision analysis.","volume":"106","author":"Axelrod","year":"2022","journal-title":"Transplantation"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1111\/ajt.15976","article-title":"Cytomegalovirus serologic matching in deceased donor kidney allocation optimizes high- and low-risk (D+R- and D-R-) profiles and does not adversely affect transplant rates.","volume":"20","author":"Lockridge","year":"2020","journal-title":"Am J Transplant"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/jama.2020.3138","article-title":"Effect of preemptive therapy vs antiviral prophylaxis on cytomegalovirus disease in seronegative liver transplant recipients with seropositive donors: a randomized clinical trial.","volume":"323","author":"Singh","year":"2020","journal-title":"JAMA"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"e01794","DOI":"10.1128\/AAC.01794-16","article-title":"Phase 2 randomized, double-blind, placebo-controlled trial of RG7667, a combination monoclonal antibody, for prevention of cytomegalovirus infection in high-risk kidney transplant recipients.","volume":"61","author":"Ishida","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1111\/ajt.14925","article-title":"A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor.","volume":"18","author":"Vincenti","year":"2018","journal-title":"Am J Transplant"},{"key":"R13-20250604","first-page":"8","article-title":"Indirect effects of CMV in the solid organ transplant patient.","volume":"1","author":"Paya","year":"1999","journal-title":"Transpl Infect Dis"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/infdis\/jiz181","article-title":"Prospective assessment of cytomegalovirus immunity in high-risk donor-seropositive\/recipient-seronegative liver transplant recipients receiving either preemptive therapy or antiviral prophylaxis.","volume":"220","author":"Limaye","year":"2019","journal-title":"J Infect Dis"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation.","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004352","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T14:14:18Z","timestamp":1749046458000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000004352","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,29]]}}}